European Journal of Cardiovascular Medicine

Background- Vaccines for covid-19 have been developed at unprecedented speed, with phase III clinical efficacy trials reporting results for some vaccines less than a year after WHO declared the pandemic.Since December2020, several vaccines have been authorized by regulators such as the European Medicines Agency, the US Food and Drug Administration, and the UK Medicines and Healthcare products Regulatory Agency. Large scale immunisation programmes are ongoing worldwide.Objective- To study and compare post vaccination events after first and second booster dose of novel corona virus vaccine. Method-The present hospital based prospective study was conducted in Dr Baba Saheb Ambedkar medical college and Hospital.The duration of study was 12 months. The details to contact the study participants were obtained from hospital vaccination centre. Participants were also contacted at vaccination centre and after taking informed consent, a history of participants was taken in the form of a questionnaire and physical conversation. Results- A total of 40.20% of the study population reported atleast one adverse event following vaccination which was mild in nature.Most common adverse event was fever (28%) followed by injection site pain (22.80%).Statistically significant difference was reported for individual adverse events like fever, injection site pain, fatigue, headache, weakness, nausea, vomiting for the first and second dose.The incidence of adverse events after first dose in covishield was significantly greater as compared to covaxin (55.14% vs 40%) with P value=0.002. Conclusion: Both vaccines exhibited short-term adverse effects, albeit they were modest and of short duration. Within this particular framework, our study gains greater significance in distributing concise safety information subsequent to immunisation. This will aid folks in their decision to accept immunisation.